Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says...

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading."